<?xml version="1.0" encoding="UTF-8"?><html>
   <div tagx="ui">1745-6215-16-5</div>
   <div tagx="ji">1745-6215</div>
   <head>
      <div tagx="dochead">Study protocol</div>
      <div tagx="bibl">
         <div tagx="title">
            <p>Intravenous iron isomaltoside 1000 administered by high single-dose infusions or standard
               medical care for the treatment of fatigue in women after postpartum haemorrhage: study
               protocol for a randomised controlled trial
            </p>
         </div>
         <ul tagx="aug">
            <li tagx="au">
               <span tagx="snm">Holm</span>
               <span tagx="fnm">Charlotte</span>
               <span tagx="insr"></span>
               <span tagx="insr"></span>
               <a href="charlotteholm@dadlnet.dk">charlotteholm@dadlnet.dk</a>
            </li>
            <li tagx="au">
               <span tagx="snm">Thomsen</span>
               <span tagx="mnm">Lykke</span>
               <span tagx="fnm">Lars</span>
               <span tagx="insr"></span>
               <a href="llt@pharmacosmos.com">llt@pharmacosmos.com</a>
            </li>
            <li tagx="au">
               <span tagx="snm">Norgaard</span>
               <span tagx="fnm">Astrid</span>
               <span tagx="insr"></span>
               <a href="astrid.noergaard@regionh.dk">astrid.noergaard@regionh.dk</a>
            </li>
            <li tagx="au">
               <span tagx="snm">Langhoff-Roos</span>
               <span tagx="fnm">Jens</span>
               <span tagx="insr"></span>
               <a href="jens.langhoff-roos@regionh.dk">jens.langhoff-roos@regionh.dk</a>
            </li>
         </ul>
         <ul tagx="insg">
            <li tagx="ins">
               <p>Department of Obstetrics, Juliane Marie Centre, Copenhagen University Hospital, Rigshospitalet,
                  Blegdamsvej 9, DK-2100 Kbh Ø Copenhagen, Denmark
               </p>
            </li>
            <li tagx="ins">
               <p>Pharmacosmos A/S, Roervangsvej 30, DK-4300 Holbaek, Denmark</p>
            </li>
            <li tagx="ins">
               <p>Section for Transfusion Medicine 2034, Capital Region Blood Bank, Copenhagen University
                  Hospital, Rigshospitalet, Blegdamsvej 9, DK-2100 Kbh Ø Copenhagen, Denmark
               </p>
            </li>
         </ul>
         <span tagx="source">Trials</span>
         <span tagx="issn">1745-6215</span>
         <span tagx="pubdate">2015</span>
         <span tagx="volume">16</span>
         <span tagx="issue">1</span>
         <span tagx="fpage">5</span>
         <a href="http://www.trialsjournal.com/content/16/1/5">http://www.trialsjournal.com/content/16/1/5</a>
         <div tagx="xrefbib">
            <div tagx="pubidlist">
               <span tagx="pubid">25588587</span>
               <span tagx="pubid">10.1186/1745-6215-16-5</span>
            </div>
         </div>
      </div>
      <div tagx="history">
         <span tagx="rec">
            <div tagx="date">
               <span tagx="day">8</span>
               <span tagx="month">7</span>
               <span tagx="year">2014</span>
            </div>
         </span>
         <span tagx="acc">
            <div tagx="date">
               <span tagx="day">10</span>
               <span tagx="month">12</span>
               <span tagx="year">2014</span>
            </div>
         </span>
         <span tagx="pub">
            <div tagx="date">
               <span tagx="day">14</span>
               <span tagx="month">1</span>
               <span tagx="year">2015</span>
            </div>
         </span>
      </div>
      <div tagx="cpyrt">
         <span tagx="year">2015</span>
         <div tagx="collab">Holm et al.; licensee BioMed Central.</div>
         <div tagx="note">This is an Open Access article distributed under the terms of the Creative Commons
            Attribution License (
            <a href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</a>), which permits unrestricted use, distribution, and reproduction in any medium, provided
            the original work is properly credited. The Creative Commons Public Domain Dedication
            waiver (
            <a href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</a>) applies to the data made available in this article, unless otherwise stated.
         </div>
      </div>
      <ul tagx="kwdg">
         <li tagx="kwd">Postpartum haemorrhage</li>
         <li tagx="kwd">Iron deficiency</li>
         <li tagx="kwd">Intravenous iron</li>
         <li tagx="kwd">Postpartum fatigue</li>
      </ul>
      <div id="abstract" tag="abstract">
         <div id="">
            <div tagx="st">
               <h2>Abstract</h2>
            </div>
            <div id="">
               <div tagx="st">
                  <h3>Background</h3>
               </div>
               <p>Postpartum haemorrhage can lead to iron deficiency with and without anaemia, the clinical
                  consequences of which include physical fatigue. Although oral iron is the standard
                  treatment, it is often associated with gastrointestinal side effects and poor compliance.
                  To date, no published randomised controlled studies have compared the clinical efficacy
                  and safety of standard medical care with intravenous administration of iron supplementation
                  after postpartum haemorrhage.
               </p>
               <p>The primary objective of this study is to compare the efficacy of an intravenous high
                  single-dose of iron isomaltoside 1000 with standard medical care on physical fatigue
                  in women with postpartum haemorrhage.
               </p>
            </div>
            <div id="">
               <div tagx="st">
                  <h3>Methods/Design</h3>
               </div>
               <p>In a single centre, open-labelled, randomised trial, women with postpartum haemorrhage
                  exceeding 700 mL will be allocated to either a single dose of 1,200 mg of iron isomaltoside
                  1000 or standard medical care. Healthy parturients with a singleton pregnancy will
                  be included within 48 hours after delivery.
               </p>
               <p>Participants will complete structured questionnaires that focus on several dimensions
                  of fatigue and mental health (Multidimensional Fatigue Inventory, Edinburgh Postnatal
                  Depression Scale and the Postpartum Questionnaire), at inclusion and at follow-up
                  visits after three days, one week, three weeks, eight weeks, and 12 weeks postpartum.
                  The primary endpoint is the aggregated change in physical fatigue score within 12 weeks
                  postpartum, as measured by a subscale of the Multidimensional Fatigue Inventory. The
                  primary objective will be considered to have been met if an intravenous high single
                  dose of iron isomaltoside 1000 is shown to be superior to standard medical care in
                  women after postpartum haemorrhage regarding physical fatigue.
               </p>
               <p>For claiming superiority, we set the minimal clinically relevant difference between
                  the mean scores at 1.8, and the assumed standard deviation at 4.2. Hence, 87 participants
                  per treatment group are needed in order to demonstrate superiority; to provide an
                  extra margin for missing data and dropouts, 200 women will be included.
               </p>
            </div>
            <div id="">
               <div tagx="st">
                  <h3>Discussion</h3>
               </div>
               <p>The study will provide evidence on relevant clinical outcomes beyond biochemical parameters
                  for intravenous iron isomaltoside 1000 compared to standard medical care in women
                  after postpartum haemorrhage.
               </p>
            </div>
            <div id="">
               <div tagx="st">
                  <h3>Trial registration</h3>
               </div>
               <p>This trial is registered with Clinicaltrials.gov (identifier: 
                  <div tagx="a">NCT01895218</div>) on 26 June 2013.
               </p>
            </div>
         </div>
      </div>
   </head>
   <div id="">
      <div tagx="st">
         <h2>Background</h2>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Postpartum iron deficiency and anaemia</h3>
         </div>
         <p>Blood loss of up to 500 mL at delivery is considered to be a normal physiological
            mechanism that brings a woman’s haemoglobin value back to the pre-pregnancy level
            
            <span tagx="abbrgrp">
               <span tagx="abbr">1</span>
               <span tagx="abbr">2</span>
            </span>. Severe postpartum haemorrhage (PPH) is defined as blood loss above 1,000 mL within
            the first 24 hours after delivery 
            <span tagx="abbrgrp">
               <span tagx="abbr">3</span>
            </span>. Full body iron stores can replete blood loss up to a maximum of 1,000 mL 
            <span tagx="abbrgrp">
               <span tagx="abbr">4</span>
            </span>, which means that many women with a blood loss between 500 and 1,000 mL will develop
            iron deficiency with or without anaemia. Therefore, in the present study of iron supplementation,
            we considered ≥700 mL blood loss to be the appropriate clinically significant criteria
            for inclusion.
         </p>
         <p>Postpartum iron deficiency anaemia may lead to several clinical consequences, the
            most prominent of which is maternal physical fatigue 
            <span tagx="abbrgrp">
               <span tagx="abbr">5</span>
            </span>. It is currently unknown whether treatment can help this fatigue or whether biochemical
            markers, such as haemoglobin (Hb), ferritin and other biomarkers, can measure the
            condition and predict clinical treatment effects.
         </p>
         <p>Breastfeeding is important for the health of the infant. Delayed onset of postpartum
            lactogenesis increases the risk of inadequate infant growth and early discontinuation
            of breastfeeding 
            <span tagx="abbrgrp">
               <span tagx="abbr">6</span>
               <span tagx="abbr">7</span>
            </span>. A retrospective Canadian study found postpartum iron deficiency anaemia to be negatively
            associated with the duration of breastfeeding 
            <span tagx="abbrgrp">
               <span tagx="abbr">8</span>
            </span>, but it is unknown whether postpartum iron deficiency anaemia is associated with
            delayed postpartum lactogenesis, or if the duration of breastfeeding can be improved
            with iron treatment after delivery.
         </p>
         <p>The clinical consequences of postpartum iron deficiency without anaemia are not known
            in detail. However, iron deficiency without anaemia in women of childbearing age is
            associated with fatigue, impaired physical work performance, deficient cognitive functions
            and mood disturbances 
            <span tagx="abbrgrp">
               <span tagx="abbr">9</span>
            </span>. Therefore, it is possible that postpartum iron deficiency without anaemia contributes
            significantly to physical fatigue in the puerperium, and that iron treatment is beneficial
            for these women and their infants.
         </p>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Intravenous iron</h3>
         </div>
         <p>The currently available intravenous iron preparations are generally considered equally
            efficacious but vary in terms of molecular size, kinetics, bioavailability and toxicology
            
            <span tagx="abbrgrp">
               <span tagx="abbr">10</span>
               <span tagx="abbr">11</span>
            </span>. The European Medicines Agency recently reviewed the safety of intravenous iron.
            It concluded that the benefits of intravenous iron are greater than their risks and
            was unable to establish a difference in the safety profiles of the products 
            <span tagx="abbrgrp">
               <span tagx="abbr">12</span>
            </span>.
         </p>
         <p>Isomaltoside 1000, the carbohydrate component in iron isomaltoside 1000 (Monofer®),
            has a mean molecular weight of 1,000 Da and consists predominantly of three to five
            glucose units. The carbohydrate isomaltoside is linear and unbranched with a low immunogenic
            potential. Iron isomaltoside 1000 has strongly bound iron within the iron isomaltoside
            formulation, which enables a controlled slow release of bioavailable iron to the iron-binding
            proteins with minimal risk of free iron toxicity 
            <span tagx="abbrgrp">
               <span tagx="abbr">13</span>
            </span>.
         </p>
         <p>To date, iron isomaltoside 1000 has been approved in Europe for the treatment of iron
            deficiency anaemia. The indications are when oral iron preparations are ineffective
            or cannot be used, or where there is a clinical need to deliver iron rapidly. Several
            studies of iron isomaltoside 1000 treatment of iron deficiency anaemia have been published,
            including the use of bolus injections and high single-dose infusions, without detected
            unexpected safety issues 
            <span tagx="abbrgrp">
               <span tagx="abbr">14</span>
               <span tagx="abbr">15</span>
               <span tagx="abbr">16</span>
               <span tagx="abbr">17</span>
            </span>.
         </p>
         <p>Iron isomaltoside 1000 was chosen for this study as it is approved for high single
            dosing of up to 20 mg/kg. The high single dose is preferable in the treatment of puerperal
            women, as they need fast correction of their iron deficit before leaving the hospital.
         </p>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Previous studies and current guidelines</h3>
         </div>
         <p>International guidelines are available for the treatment of iron deficiency anaemia
            in pregnancy and the postpartum period 
            <span tagx="abbrgrp">
               <span tagx="abbr">18</span>
               <span tagx="abbr">19</span>
               <span tagx="abbr">20</span>
               <span tagx="abbr">21</span>
            </span>. These guidelines recommend oral iron supplementation in mild anaemia, intravenous
            iron in moderate anaemia and when oral iron supplementation is not tolerated, and
            allogeneic red blood cell (RBC) transfusion in severe and symptomatic cases. These
            guidelines do not deal with screening for or treatment of iron deficiency without
            anaemia.
         </p>
         <p>Denmark has no published national guideline on the screening or treatment of postpartum
            iron deficiency with or without anaemia. In clinical practice, doctors usually recommend
            oral iron supplementation to parturients with PPH, and RBC transfusion to those with
            severe symptoms of anaemia. Since puerperal women with a Hb level of ≤6.5 g/dL (4.0 mmol/L)
            often have severe symptoms of anaemia, we will not include these parturients in the
            study.
         </p>
         <p>No prospective randomised clinical studies have yet assessed the effect of intravenous
            iron supplementation in comparison to standard medical care in women after PPH with
            a clinical outcome as the primary endpoint. There have been 10 randomised controlled
            studies that have compared intravenous iron to oral iron supplementation in women
            with diagnosed postpartum iron deficiency anaemia 
            <span tagx="abbrgrp">
               <span tagx="abbr">22</span>
               <span tagx="abbr">23</span>
               <span tagx="abbr">24</span>
               <span tagx="abbr">25</span>
               <span tagx="abbr">26</span>
               <span tagx="abbr">27</span>
               <span tagx="abbr">28</span>
               <span tagx="abbr">29</span>
               <span tagx="abbr">30</span>
               <span tagx="abbr">31</span>
            </span>. The inclusion criteria of these studies were Hb concentration up to 10 days after
            delivery, and the primary study endpoints were Hb concentration, iron parameters and
            comparisons thereof. Generally, these studies have demonstrated improvement of Hb
            and iron parameters, favouring intravenous iron. With regard to safety, oral iron
            was associated with gastrointestinal side effects in up to 30% of the participants,
            with a compliance rate as low as 50%. These findings must be balanced against the
            very low risk of severe hypersensitivity reactions with intravenous iron 
            <span tagx="abbrgrp">
               <span tagx="abbr">12</span>
            </span>.
         </p>
         <p>Hb concentration and other biochemical parameters are influenced by the haemodynamic
            changes, and are therefore considered unreliable for diagnosing iron deficiency anaemia
            in the first week(s) after giving birth 
            <span tagx="abbrgrp">
               <span tagx="abbr">32</span>
            </span>. However, it is crucial that these women can benefit from treatment in the clinically
            important first days after delivery. In the present study, we have chosen to include
            women based on their clinically estimated blood loss after delivery, and we hypothesise
            that women with clinically significant PPH will have an increased risk of developing
            iron deficiency with or without anaemia.
         </p>
         <p>We believe that iron treatment should be administered in order to improve clinical
            symptoms of iron deficiency with or without anaemia, not just to improve biochemical
            markers. This is in accordance with a systematic review, which concluded that there
            is a lack of high-quality studies with clinical outcomes 
            <span tagx="abbrgrp">
               <span tagx="abbr">33</span>
            </span>. Therefore, we have decided that the primary outcome in the present study will be
            a clinically significant improvement in the physical fatigue score between the treatment
            groups. We hypothesise that intravenous iron is superior to standard medical care.
         </p>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Objective</h3>
         </div>
         <p>The primary objective of this study is to compare the efficacy of intravenous high
            single doses of iron isomaltoside 1000 to standard medical care on physical fatigue
            in women with PPH.
         </p>
      </div>
   </div>
   <div id="">
      <div tagx="st">
         <h2>Methods/Design</h2>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Study design</h3>
         </div>
         <p>The study will be a randomised, comparative, open-label single-centre study with a
            1:1 allocation ratio. The trial is a company-sponsored interventional trial conducted
            according to International Conference on Harmonization-Good Clinical Practice (ICH-GCP)
            guidelines 
            <span tagx="abbrgrp">
               <span tagx="abbr">34</span>
            </span>.
         </p>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Inclusion criteria</h3>
         </div>
         <p>Women, regardless of mode of delivery, will be eligible for inclusion in the study
            if they fulfil the following criteria: (1) they have signed the informed consent form,
            and (2) they have either (a) PPH ≥700 and ≤1,000 mL or (b) PPH &gt;1,000 mL and Hb &gt;6.5 g/dL
            (4.0 mmol/L) measured at &gt;12 hours after delivery (Figure 
            <div tagx="figr">1</div>).
         </p>
         <div tagx="fig">
            <div tagx="title">
               <p>Figure 1</p>
            </div>
            <caption>
               <p>Trial flow</p>
            </caption>
            <div tagx="text">
               <p>
                  <b>Trial flow.</b> Women with postpartum haemorrhage ≥700 and ≤1,000 mL or PPH &gt;1,000 mL and haemoglobin
                  &gt;6.5 g/dL (4.0 mmol/L) within 48 hours of delivery will be screened for inclusion
                  and exclusion and asked for consent to participate. Baseline questionnaires are completed
                  and blood samples are taken. The participants are randomised to either intravenous
                  iron isomaltoside 1000 or standard medical care. Follow-up visits with completion
                  of questionnaires, blood samples and maternal milk samples are performed at three
                  days, and one, three, eight and 12 weeks after intervention. (EPDS: Edinburgh Postnatal
                  Depression Scale; Hb: haemoglobin; HELLP: haemolysis, elevated liver enzymes, and
                  low platelet count; MFI: Multidimensional Fatigue Inventory; PPH: postpartum haemorrhage;
                  PPQ: Postpartum Questionnaire; RBC: red blood cells; subMFI: subscale of the Multidimensional
                  Fatigue Inventory; subPPQ: subscale of the Postpartum Questionnaire).
               </p>
            </div>
            <div tagx="graphic"></div>
         </div>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Exclusion criteria</h3>
         </div>
         <p>Exclusion criteria: age &lt;18 years; multiple births; peripartum RBC transfusion; known
            iron overload or disturbances in the utilisation of iron (such as haemochromatosis
            or haemosiderosis); known hypersensitivity to parenteral iron or any excipients in
            the investigational drug products; a history of active asthma within the previous
            five years; a history of multiple allergies; known decompensated liver cirrhosis or
            active hepatitis; haemolysis, elevated liver enzymes, and low platelet count (HELLP)
            syndrome; active acute infection (clinical symptoms or fever above 38.5°C); rheumatoid
            arthritis; history of anaemia caused by a known haematological disorder other than
            iron deficiency; inability to read, speak and understand the Danish language; participation
            in any other clinical study where the study drug has not passed five half-lives prior
            to the baseline and any other medical condition that, in the opinion of the investigator,
            may cause the parturient to be unsuitable for completion of the study or place her
            at potential risk from participating in the study.
         </p>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Randomisation</h3>
         </div>
         <p>Participants will be randomised using an interactive web response system (eClinical
            OS™, Merge Healthcare, Morrisville, NC, United States). The randomisation lists will
            be prepared centrally by the contract research organization BioStata ApS, Birkerød,
            Denmark using a validated computer program. The randomisation will be stratified by
            bleeding volume (PPH: 700 to 1,000 mL or PPH &gt;1,000 mL). Within each bleeding category,
            there will be a 1:1 randomisation ratio to one of the two treatment groups.
         </p>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Intervention</h3>
         </div>
         <p>The participants will be randomised to either standard medical care or iron isomaltoside
            1000. Standard medical care (current treatment practice) at the Department of Obstetrics,
            Copenhagen University Hospital, Rigshospitalet is typically to recommend women with
            PPH to either continue oral iron supplementation, as during pregnancy (the Danish
            Health and Medicines Authority recommends 40 to 50 mg oral iron supplementation daily
            
            <span tagx="abbrgrp">
               <span tagx="abbr">35</span>
            </span>), or to take 100 mg oral iron one or two times daily for a variable time period.
            The actual use of iron supplementation, including specific preparation, dose and duration
            of treatment, will be monitored at each follow-up visit.
         </p>
         <p>Immediately after acute bleeding such as PPH, the Hb level is inaccurate for calculating
            individual dosing of iron supplementation. Hence, the iron isomaltoside 1000 fixed
            dosage in this study is based on the expected iron deficiency in women after PPH.
            Body iron stores are approximately 500 to 750 mg and the average iron loss through
            PPH is approximately 500 mg, as 500 mL blood loss equals 250 mg iron loss 
            <span tagx="abbrgrp">
               <span tagx="abbr">4</span>
            </span>. In previous studies of women with postpartum anaemia, oral iron treatment dosages
            were 130 to 200 mg per day over a period of 42 to 84 days, resulting in a total average
            dose of 11.088 mg 
            <span tagx="abbrgrp">
               <span tagx="abbr">23</span>
               <span tagx="abbr">24</span>
               <span tagx="abbr">25</span>
               <span tagx="abbr">26</span>
               <span tagx="abbr">27</span>
            </span>. The intestinal iron absorption varies considerably but is believed to be a maximum
            of 10% 
            <span tagx="abbrgrp">
               <span tagx="abbr">36</span>
            </span>, resulting in a total expected absorption of 1,100 to 1,200 mg. Thus, the cumulated
            iron dosages in these studies are in accordance with the chosen treatment dose in
            this study.
         </p>
         <p>In the group allocated to iron isomaltoside 1000, Pharmacosmos A/S, Holbaek, Denmark,
            the iron replacement dose is set to 1,200 mg. The dose is diluted in 100 mL 0.9% sodium
            chloride, Fresenius Kabi AG, Bad Homburg, Germany, and administered over a period
            of approximately 15 minutes. No test dose is applied. Participants with a pre-pregnancy
            weight &lt;45 kg will receive a reduced single dose of 1,000 mg iron isomaltoside 1000,
            administered in the same fashion. In both treatment groups, participants may be given
            a ‘rescue’ allogeneic RBC transfusion if this procedure is clinically indicated.
         </p>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Setting, location and follow-up</h3>
         </div>
         <p>The parturients will be screened for inclusion in the study over an 18-month period
            at the Department of Obstetrics, Copenhagen University Hospital, Rigshospitalet, a
            tertiary hospital that performs between 6,000 and 7,000 deliveries per year. Eligible
            parturients are informed about the study and must provide their written consent within
            48 hours after delivery. The duration for each individual participant is approximately
            12 weeks and involves five follow-up visits by a midwife at the participant’s home.
            The timeframes of the follow-up visits are three days (between two and four days),
            one week (between six and eight days), three weeks (between 19 and 23 days), eight
            weeks (between seven and nine weeks) and 12 weeks (between 11 and 13 weeks).
         </p>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Outcomes and safety measures</h3>
         </div>
         <p>The primary outcome is the aggregated change in physical fatigue score within 12 weeks
            postpartum, as measured by a subscale of the Multidimensional Fatigue Inventory (MFI)
            
            <span tagx="abbrgrp">
               <span tagx="abbr">37</span>
            </span>. Secondary efficacy outcomes include changes in the Hb concentration, 
            <i>p-</i>ferritin, 
            <i>p-</i>iron, 
            <i>p-</i>transferrin, transferrin saturation, reticulocyte count, mean reticulocyte Hb content,
            other MFI and Postpartum Questionnaire (PPQ) fatigue items, symptoms of postpartum
            depression, time of postpartum lactogenesis, time of discontinuation of breastfeeding
            and transfusion of allogeneic RBCs.
         </p>
         <p>The safety outcomes are discontinuation due to intolerance, frequency, nature and
            severity of adverse events, vital signs, and 
            <i>p</i>-sodium, 
            <i>p-</i>potassium, 
            <i>p-</i>calcium, 
            <i>p-</i>phosphate, 
            <i>p-</i>urea, 
            <i>p-</i>creatinine, 
            <i>p-</i>albumin, 
            <i>p</i>-bilirubin, 
            <i>p</i>-aspartate aminotransferase and 
            <i>p</i>-alanine aminotransferase levels. Other outcomes are maternal milk iron level, anaemia
            symptoms and gastrointestinal symptoms.
         </p>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Questionnaires</h3>
         </div>
         <p>We will use the three following self-reported questionnaires: the fatigue measures
            MFI and PPQ and the depression measure Edinburgh Postnatal Depression Scale (EPDS)
            
            <span tagx="abbrgrp">
               <span tagx="abbr">38</span>
            </span>. Of these, the MFI includes the scale of physical fatigue, which is the primary endpoint
            of this investigation.
         </p>
         <p>The MFI has been found to have high feasibility, reliability and validity in chronically
            anaemic women 
            <span tagx="abbrgrp">
               <span tagx="abbr">39</span>
            </span> and in postpartum women 
            <span tagx="abbrgrp">
               <span tagx="abbr">40</span>
            </span>. The MFI covers the following dimensions: general fatigue, physical fatigue, reduced
            activity, reduced motivation and mental fatigue. The MFI consists of 20 statements
            for which the participant indicates, on a five-point scale, the extent to which the
            particular statement applies to her. The statements refer to aspects of fatigue experienced
            during the previous days. Higher scores indicate a higher degree of fatigue.
         </p>
         <p>The PPQ is a novel and yet to be validated instrument that was developed for this
            study to measure fatigue in parturients [see Additional file 
            <div tagx="supplr">1</div> (in Danish)]. It consists of a visual analogue scale of how tired the participant
            is and five questions regarding fatigue. The first question concerns what the participant
            experiences as most troublesome, pain or fatigue. The second question concerns whether
            the fatigue is experienced most physically or mentally. For each of the first two
            questions the participant is asked to underline one of five possible responses. The
            last three questions explore how the fatigue influences breastfeeding, contact with
            the newborn and to what extend the participant asks for help with nappy changing.
            The participant is asked to indicate, on a four-point scale, the extent of the influence
            of the fatigue. Higher scores from the last three questions indicate a higher degree
            of fatigue.
         </p>
         <div tagx="suppl">
            <div tagx="title">
               <p>Additional file 1</p>
            </div>
            <div tagx="text">
               <p>
                  <b>Postpartum Questionnaire.</b>
               </p>
            </div>
            <div tagx="file">
               <p>Click here for file</p>
            </div>
         </div>
         <p>The EPDS is a screening instrument that was developed to detect symptoms of depression
            in puerperal women. A number of studies have confirmed that the EPDS is both reliable
            and sensitive 
            <span tagx="abbrgrp">
               <span tagx="abbr">41</span>
            </span>. The EPDS consists of 10 questions. Participants are asked to underline one of four
            possible responses that comes closest to how she has been feeling during the previous
            seven days. The maximum score is 30 and a score of 10 or higher indicates possible
            depression.
         </p>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Monitoring and data collection</h3>
         </div>
         <p>The data collection tool for this study is an electronic case report form. Data necessary
            for analyses and reporting will be entered into a validated and secured data system.
            Clinical data management is performed in accordance with applicable standards and
            data cleaning procedures.
         </p>
         <p>A clinical research associate (CRA) from a contract research organisation will monitor
            the study for protocol compliance, verifying that safety procedures and the rights
            of participants are being protected. The CRA will also verify that the study is conducted
            in accordance with the currently approved protocol and any other study agreements,
            ICH-GCP guidelines and all applicable regulatory requirements. The CRA will also monitor
            and verify that data are authentic, accurate and complete.
         </p>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Number of participants</h3>
         </div>
         <p>The following hypothesis will be tested: iron isomaltoside 1000 is superior to standard
            medical care in the treatment of iron deficiency in women with PPH with or without
            anaemia, measured primarily by a reduction in physical fatigue. The null hypothesis
            of no difference between the treatment groups will be tested against the alternative
            by constructing a two-sided 95% confidence interval of the difference in aggregated
            change in physical fatigue score from baseline to week 12 between the two treatment
            groups. The sample size calculations are based on the primary endpoint, aggregated
            change in physical fatigue score from baseline to week 12. A two-sided significance
            level of 5% is used and the power is set to 80%.
         </p>
         <p>The use of the physical fatigue subscale of MFI allows a maximum change of 16 points.
            Based on clinical judgement and consensus between all authors, we wish to see a difference
            greater than 10% for claiming clinically relevant superiority. Hence, we set the minimal
            clinically relevant difference to 1.8. In a previous study, the standard deviation
            was found to be approximately 4.2 
            <span tagx="abbrgrp">
               <span tagx="abbr">40</span>
            </span>. Therefore, 87 patients per treatment group are needed in order to demonstrate superiority.
            With a margin for missing data and a dropout rate of 13%, 200 women will be included.
         </p>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Statistical methods and data analysis</h3>
         </div>
         <p>All tests are pre-specified in a statistical analysis plan. The primary analysis population
            will be the full analysis set, including all randomised participants who received
            the study drug and have at least one post-baseline physical fatigue score. The primary
            endpoint is the aggregated change in the physical fatigue score from baseline to week
            12. This will be calculated as the area under the curve of the changes in the physical
            fatigue score from baseline to each visit until week 12, divided by the number of
            scheduled days (observation period). The area under the curve will be calculated using
            the linear trapezoidal method and scheduled days. The primary endpoint will be analysed
            using an analysis of variance model, with treatment and amount of PPH (700 to 1,000 mL
            or &gt;1,000 mL) as factors, and baseline MFI physical fatigue score as the covariate.
            The estimated treatment differences (iron isomaltoside 1000 versus standard medical
            care) expressed as contrasts of the adjusted means will be presented with corresponding
            95% confidence intervals and the 
            <i>P</i> value. Iron isomaltoside 1000 will be considered superior to standard medical care
            if the lower limit of the 95% confidence interval is above zero. We will also perform
            a per protocol analysis excluding participants with major protocol deviations, such
            as rescue allogeneic RBC transfusion.
         </p>
         <p>All statistical tests of the efficacy endpoints will be two-sided and performed on
            a 5% significance level. Estimated treatment differences and 95% confidence limits
            will be presented together with the corresponding 
            <i>P</i> value. Continuous secondary endpoints will be analysed by a mixed model for repeated
            measurements, including visit and treatment-by-visit, and PPH (700 to 1,000 mL or
            &gt;1,000 mL) as factors, the baseline value as the covariate, and the subject as the
            random effect. If no baseline value is measured for the endpoint in question, the
            value at the first measured time will be included as the covariate. An unstructured
            covariance structure will be used to model the within-subject errors and the estimation
            method will be a restricted maximum likelihood-based approach. The analysis will be
            based on the ‘missing at random’ assumption and performed using the data from each
            observed case. ‘Proportion’ endpoints will be analysed by logistic regression with
            treatment as the factor. Where relevant, the baseline value of the parameter in question
            will be included as the covariate. Time to postpartum lactogenesis and time to discontinuation
            of breastfeeding will be assessed and analysed using Kaplan-Meier curves and compared
            between treatments using a log-rank test. The laboratory data will be analysed as
            described for the continuous variables above. Adverse events will be summary tabulated
            using the latest version of the Medical Dictionary for Regulatory Activities body
            system and preferred term indicating the number and percentage of participants and
            the number of events. The number of participants who experience an adverse drug reaction,
            including suspected unexpected serious adverse reactions, will be compared between
            treatment groups.
         </p>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Consent and ethical considerations</h3>
         </div>
         <p>Women planning to give birth at the Department of Obstetrics, Copenhagen University
            Hospital, Rigshospitalet have received written information about the study at one
            of their antenatal midwife consultations. When a parturient fulfils the inclusion
            criteria, she will be asked to participate in the study after receiving oral and written
            information from an investigator. In obtaining and documenting informed consent, the
            investigator will comply with any applicable regulatory requirements, and will adhere
            to ICH-GCP and the Declaration of Helsinki. The National Committee on Biomedical Research
            Ethics (approval number: H-4-2013-019) and the Danish Medicines Agency (approval number:
            EudraCT 2012-005782-12) have approved the study. The trial is registered at Clinicaltrials.gov
            (identifier: NCT01895218).
         </p>
      </div>
   </div>
   <div id="">
      <div tagx="st">
         <h2>Discussion</h2>
      </div>
      <p>The aim of this study is to compare a new treatment option (iron isomaltoside 1000)
         to standard medical care. The choice of the latter active comparator, ‘the drug of
         first choice’, enables us to use the results of this study for assessing the potential
         additional benefit of iron isomaltoside 1000 in a clinical setting.
      </p>
      <p>The standard medical care treatment group does not receive a general specified recommendation
         of oral iron supplementation. We considered that standard treatment, as defined by
         the individualised regimen chosen by the parturient and her midwife, was the proper
         comparator. A pregnant woman usually takes oral iron supplementation from early pregnancy
         and finds a preparation and a dose that is suitable for her. A general fixed regimen
         might cause gastrointestinal side effects in some individuals, and a possible insufficient
         effect in others. Therefore, the fixed regimen would be suboptimal as a comparator
         compared with the standard individualised regimen, which is current practice in the
         Capital Region of Denmark. The actual use of oral iron, including specific preparation,
         dose and duration of treatment, is registered at each follow-up visit.
      </p>
      <p>The individualised regimen design implies that we were not able to blind the randomisation
         in this trial. Also, since iron tablets colour the stools, we assessed that a double-blinded
         design would be unfeasible and would not contribute additional scientific merit. Accordingly,
         most previously published randomised controlled trials with iron treatment of women
         after childbirth have not been double-blinded 
         <span tagx="abbrgrp">
            <span tagx="abbr">23</span>
            <span tagx="abbr">24</span>
            <span tagx="abbr">25</span>
            <span tagx="abbr">26</span>
            <span tagx="abbr">27</span>
         </span>.
      </p>
      <p>The strength of this trial is the fact that it will be conducted at a single centre.
         This means that the standard medical care is less diverse than it might otherwise
         be and we can ensure a full overview of all parturients with PPH ≥700 mL in the time
         period of inclusion, which will enable us to collect detailed information about those
         excluded and the reasons why not.
      </p>
      <p>The risk of bias by selecting the subjective endpoint physical fatigue in an open-label
         study is an inherent weakness of the study. Fatigue is an important clinical endpoint
         that has consistently been shown to be affected by iron deficiency and iron deficiency
         anaemia. However, fatigue in the postpartum period is highly dependent on various
         attributes, including the mode and outcome of delivery, the duration of labour, medical
         comorbidities, the health of the infant and a host of social and environmental factors.
         Nevertheless, this design was previously used in a randomised controlled study in
         a similar population, where an open-label design and subjective primary endpoint were
         chosen for the most clinically relevant design 
         <span tagx="abbrgrp">
            <span tagx="abbr">42</span>
         </span>.
      </p>
      <p>The instrument used for measuring the primary endpoint is the physical fatigue subscale
         of the MFI. We selected this instrument due to its previous validation, including
         the findings of high feasibility and reliability in the postpartum population, specifically
         its use for measuring fatigue in parturients that experienced PPH. However, no validated
         questionnaires have been specifically developed for measuring postpartum fatigue.
         Although some available questionnaires for measuring fatigue have been validated for
         this population, they are all constructed to measure fatigue in other populations,
         often cancer or other chronic ill patients. Therefore, we developed a new questionnaire
         (PPQ) that is designed specifically to measure fatigue among puerperal women. A further
         objective of this study is to assess and validate its ability to measure fatigue in
         women after PPH.
      </p>
   </div>
   <div id="">
      <div tagx="st">
         <h2>Trial status</h2>
      </div>
      <p>The trial was initiated and the first parturient was included in May 2013. Inclusion
         and randomisation are ongoing and expected to be finished in August 2014.
      </p>
   </div>
   <div id="">
      <div tagx="st">
         <h2>Abbreviations</h2>
      </div>
      <p>CRA: clinical research associate; EPDS: Edinburgh Postnatale Depression Scale; Hb:
         haemoglobin; HELLP: haemolysis, elevated liver enzymes, and low platelet count; ICH-GCP:
         International Conference on Harmonization – Good Clinical Practice; MFI: Multidimensional
         Fatigue Inventory; PPH: postpartum haemorrhage; PPQ: Postpartum questionnaire; RBC:
         red blood cells.
      </p>
   </div>
   <div id="">
      <div tagx="st">
         <h2>Competing interests</h2>
      </div>
      <p>CH is an industrial PhD student and LLT is employed by Pharmacosmos A/S. JLR is the
         primary investigator employed by the Department of Obstetrics, Copenhagen University
         Hospital, Rigshospitalet, and AN is the primary investigator of an ongoing Pharmacosmos
         A/S-sponsored clinical trial. The institution receives a fee per patient.
      </p>
   </div>
   <div id="">
      <div tagx="st">
         <h2>Authors’ contributions</h2>
      </div>
      <p>CH, JLR, LLT and AN were involved in the conception and design of the study. All authors
         were involved in drafting the protocol and revising it critically. All authors have
         approved the final manuscript.
      </p>
   </div>
   <div tagx="bm">
      <div tagx="ack">
         <div id="">
            <div tagx="st">
               <h2>Acknowledgements</h2>
            </div>
            <p>The study is sponsored and fully funded by Pharmacosmos A/S. The authors are grateful
               to Jens K Slott Jensen MSc who provided statistical support. The sponsor paid for
               this assistance.
            </p>
         </div>
      </div>
      <div tagx="refgrp">
         <div tagx="bibl">
            <div tagx="title">
               <p>The Significance of blood loss at delivery</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Gyte</span>
                  <span tagx="fnm">G</span>
               </li>
            </ul>
            <span tagx="source">MIDIRS Midwifery Digest</span>
            <span tagx="pubdate">1992</span>
            <span tagx="volume">2</span>
            <span tagx="fpage">88</span>
            <span tagx="lpage">92</span>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Uterine emergencies. Atony, inversion, and rupture</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Ripley</span>
                  <span tagx="fnm">DL</span>
               </li>
            </ul>
            <span tagx="source">Obstet Gynecol Clin N Am</span>
            <span tagx="pubdate">1999</span>
            <span tagx="volume">26</span>
            <span tagx="fpage">419</span>
            <span tagx="lpage">34</span>
            <div tagx="xrefbib">
               <span tagx="pubid">10.1016/S0889-8545(05)70087-5</span>
            </div>
         </div>
         <div tagx="bibl">
            <ul tagx="aug">
               <li tagx="au">
                  <div tagx="cnm">WHO</div>
               </li>
            </ul>
            <span tagx="source">WHO Recommendations for the Prevention and Treatment of Postpartum Haemorrhage</span>
            <div tagx="publisher">Geneva: World Health Organization Press</div>
            <span tagx="pubdate">2012</span>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>New insights into erythropoiesis: the roles of folate, vitamin B, and iron*</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Koury</span>
                  <span tagx="fnm">MJ</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Ponka</span>
                  <span tagx="fnm">P</span>
               </li>
            </ul>
            <span tagx="source">Annu Rev Nutr</span>
            <span tagx="pubdate">2004</span>
            <span tagx="volume">24</span>
            <span tagx="fpage">105</span>
            <span tagx="lpage">31</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1146/annurev.nutr.24.012003.132306</span>
                  <span tagx="pubid">15189115</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Longitudinal changes in fatigue and energy during pregnancy and the postpartum period</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Lee</span>
                  <span tagx="fnm">KA</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Zaffke</span>
                  <span tagx="fnm">ME</span>
               </li>
            </ul>
            <span tagx="source">J Obstetric Gynecol Neonatal Nursing</span>
            <span tagx="pubdate">1999</span>
            <span tagx="volume">28</span>
            <span tagx="fpage">183</span>
            <span tagx="lpage">91</span>
            <div tagx="xrefbib">
               <span tagx="pubid">10.1111/j.1552-6909.1999.tb01983.x</span>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Risk factors for suboptimal infant breastfeeding behavior, delayed onset of lactation,
                  and excess neonatal weight loss
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Dewey</span>
                  <span tagx="fnm">KG</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Nommsen-Rivers</span>
                  <span tagx="fnm">LA</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Heinig</span>
                  <span tagx="fnm">MJ</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Cohen</span>
                  <span tagx="fnm">RJ</span>
               </li>
            </ul>
            <span tagx="source">Pediatrics</span>
            <span tagx="pubdate">2003</span>
            <span tagx="volume">112</span>
            <span tagx="fpage">607</span>
            <span tagx="lpage">19</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1542/peds.112.3.607</span>
                  <span tagx="pubid">12949292</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Does delayed perception of the onset of lactation shorten breastfeeding duration?</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Chapman</span>
                  <span tagx="fnm">DJ</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Pérez-Escamilla</span>
                  <span tagx="fnm">R</span>
               </li>
            </ul>
            <span tagx="source">J Hum Lact</span>
            <span tagx="pubdate">1999</span>
            <span tagx="volume">15</span>
            <span tagx="fpage">107</span>
            <span tagx="lpage">11</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1177/089033449901500207</span>
                  <span tagx="pubid">10578785</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Is there a link between postpartum anemia and discontinuation of breastfeeding?</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Rioux</span>
                  <span tagx="fnm">FM</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Savoie</span>
                  <span tagx="fnm">N</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Allard</span>
                  <span tagx="fnm">J</span>
               </li>
            </ul>
            <span tagx="source">Can J Diet Pract Res</span>
            <span tagx="pubdate">2006</span>
            <span tagx="volume">67</span>
            <span tagx="fpage">72</span>
            <span tagx="lpage">6</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.3148/67.2.2006.72</span>
                  <span tagx="pubid">16759433</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Have we forgotten the significance of postpartum iron deficiency?</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Bodnar</span>
                  <span tagx="fnm">LM</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Cogswell</span>
                  <span tagx="fnm">ME</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">McDonald</span>
                  <span tagx="fnm">T</span>
               </li>
            </ul>
            <span tagx="source">Am J Obstet Gynecol</span>
            <span tagx="pubdate">2005</span>
            <span tagx="volume">193</span>
            <span tagx="fpage">36</span>
            <span tagx="lpage">44</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1016/j.ajog.2004.12.009</span>
                  <span tagx="pubid">16021056</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Structure/histotoxicity relationship of parenteral iron preparations</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Geisser</span>
                  <span tagx="fnm">P</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Baer</span>
                  <span tagx="fnm">M</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Schaub</span>
                  <span tagx="fnm">E</span>
               </li>
            </ul>
            <span tagx="source">Arzneimittelforschung</span>
            <span tagx="pubdate">1992</span>
            <span tagx="volume">42</span>
            <span tagx="fpage">1439</span>
            <span tagx="lpage">52</span>
            <div tagx="xrefbib">
               <span tagx="pubid">1288508</span>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Ferric carboxymaltose: a review of its use in iron-deficiency anaemia</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Lyseng-Williamson</span>
                  <span tagx="fnm">KA</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Keating</span>
                  <span tagx="fnm">GM</span>
               </li>
            </ul>
            <span tagx="source">Drugs</span>
            <span tagx="pubdate">2009</span>
            <span tagx="volume">69</span>
            <span tagx="fpage">739</span>
            <span tagx="lpage">56</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.2165/00003495-200969060-00007</span>
                  <span tagx="pubid">19405553</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <ul tagx="aug">
               <li tagx="au">
                  <div tagx="cnm">European Medicines Agency</div>
               </li>
            </ul>
            <span tagx="source">Assessments Report for: Iron Containing Intravenous (IV) Medicinal Products</span>
            <div tagx="publisher">London: European Medicines Agency</div>
            <span tagx="pubdate">2013</span>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer),
                  a new intravenous iron preparation and its clinical implications
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Jahn</span>
                  <span tagx="fnm">MR</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Andreasen</span>
                  <span tagx="fnm">HB</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Fütterer</span>
                  <span tagx="fnm">S</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Nawroth</span>
                  <span tagx="fnm">T</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Schünemann</span>
                  <span tagx="fnm">V</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Kolb</span>
                  <span tagx="fnm">U</span>
               </li>
               <div tagx="etal"></div>
            </ul>
            <span tagx="source">Eur J Pharm Biopharm</span>
            <span tagx="pubdate">2011</span>
            <span tagx="volume">78</span>
            <span tagx="fpage">480</span>
            <span tagx="lpage">91</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1016/j.ejpb.2011.03.016</span>
                  <span tagx="pubid">21439379</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Effects of administration of iron isomaltoside 1000 in patients with chronic heart
                  failure. A pilot study
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Hildebrandt</span>
                  <span tagx="fnm">PR</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Bruun</span>
                  <span tagx="fnm">NE</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Nielsen</span>
                  <span tagx="fnm">OW</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Pantev</span>
                  <span tagx="fnm">E</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Shiva</span>
                  <span tagx="fnm">F</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Videbæk</span>
                  <span tagx="fnm">L</span>
               </li>
               <div tagx="etal"></div>
            </ul>
            <span tagx="source">Transfusion Altern Transfusion Med</span>
            <span tagx="pubdate">2010</span>
            <span tagx="volume">11</span>
            <span tagx="fpage">131</span>
            <span tagx="lpage">7</span>
            <div tagx="xrefbib">
               <span tagx="pubid">10.1111/j.1778-428X.2010.01145.x</span>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Iron isomaltoside 1000: a new intravenous iron for treating iron deficiency in chronic
                  kidney disease
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Wikström</span>
                  <span tagx="fnm">B</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Bhandari</span>
                  <span tagx="fnm">S</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Barany</span>
                  <span tagx="fnm">P</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Kalra</span>
                  <span tagx="fnm">PA</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Ladefoged</span>
                  <span tagx="fnm">S</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Wilske</span>
                  <span tagx="fnm">J</span>
               </li>
               <div tagx="etal"></div>
            </ul>
            <span tagx="source">J Nephrol</span>
            <span tagx="pubdate">2011</span>
            <span tagx="volume">24</span>
            <span tagx="fpage">589</span>
            <span tagx="lpage">96</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.5301/JN.2011.6248</span>
                  <span tagx="pubid">21240875</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Pharmacokinetics of iron isomaltoside 1000 in patients with inflammatory bowel disease</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Nordfjeld</span>
                  <span tagx="fnm">K</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Andreasen</span>
                  <span tagx="fnm">H</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Thomsen</span>
                  <span tagx="fnm">LL</span>
               </li>
            </ul>
            <span tagx="source">Drug Design Dev Therapy</span>
            <span tagx="pubdate">2012</span>
            <span tagx="volume">6</span>
            <span tagx="fpage">43</span>
            <span tagx="lpage">51</span>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>A randomized, open-label, non-inferiority study of intravenous iron isomaltoside 1,000
                  (Monofer) compared with oral iron for treatment of anemia in IBD (PROCEED)
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Reinisch</span>
                  <span tagx="fnm">W</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Staun</span>
                  <span tagx="fnm">M</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Tandon</span>
                  <span tagx="fnm">RK</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Altorjay</span>
                  <span tagx="fnm">I</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Thillainayagam</span>
                  <span tagx="fnm">AV</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Gratzer</span>
                  <span tagx="fnm">C</span>
               </li>
               <div tagx="etal"></div>
            </ul>
            <span tagx="source">Am J Gastroenterol</span>
            <span tagx="pubdate">2013</span>
            <span tagx="volume">108</span>
            <span tagx="fpage">1877</span>
            <span tagx="lpage">88</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1038/ajg.2013.335</span>
                  <span tagx="pubid">3853365</span>
                  <span tagx="pubid">24145678</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>UK guidelines on the management of iron deficiency in pregnancy</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Pavord</span>
                  <span tagx="fnm">S</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Myers</span>
                  <span tagx="fnm">B</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Robinson</span>
                  <span tagx="fnm">S</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Allard</span>
                  <span tagx="fnm">S</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Strong</span>
                  <span tagx="fnm">J</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Oppenheimer</span>
                  <span tagx="fnm">C</span>
               </li>
            </ul>
            <span tagx="source">Br J Haematol</span>
            <span tagx="pubdate">2012</span>
            <span tagx="volume">156</span>
            <span tagx="fpage">588</span>
            <span tagx="lpage">600</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1111/j.1365-2141.2011.09012.x</span>
                  <span tagx="pubid">22512001</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Expert recommendations for the diagnosis and treatment of iron-deficiency anemia during
                  pregnancy and the postpartum period in the Asia-Pacific region
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Breymann</span>
                  <span tagx="fnm">C</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Bian</span>
                  <span tagx="fnm">X</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Blanco-Capito</span>
                  <span tagx="fnm">LR</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Chong</span>
                  <span tagx="fnm">C</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Mahmud</span>
                  <span tagx="fnm">G</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Rehman</span>
                  <span tagx="fnm">R</span>
               </li>
            </ul>
            <span tagx="source">J Perinat Med</span>
            <span tagx="pubdate">2011</span>
            <span tagx="volume">39</span>
            <span tagx="fpage">113</span>
            <span tagx="lpage">21</span>
            <div tagx="xrefbib">
               <span tagx="pubid">21070128</span>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Diagnosis and treatment of iron-deficiency anaemia during pregnancy and postpartum</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Breymann</span>
                  <span tagx="fnm">C</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Hovegger</span>
                  <span tagx="fnm">C</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Holzgreve</span>
                  <span tagx="fnm">W</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Surbek</span>
                  <span tagx="fnm">D</span>
               </li>
            </ul>
            <span tagx="source">Arch Gynecol Obstet</span>
            <span tagx="pubdate">2010</span>
            <span tagx="volume">282</span>
            <span tagx="fpage">577</span>
            <span tagx="lpage">80</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1007/s00404-010-1532-z</span>
                  <span tagx="pubid">20577752</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Eisenmangelanämie in der Schwangerschaft und postpartum</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Kiss</span>
                  <span tagx="fnm">H</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Konnaris</span>
                  <span tagx="fnm">C</span>
               </li>
            </ul>
            <span tagx="source">Österreichische Gesellschaft Gynäkologie Geburtshilfe</span>
            <span tagx="pubdate">2011</span>
            <div tagx="note">[in German] [
               <a href="http://www.oeggg.at/fileadmin/user_upload/downloads/Leitlinien/2011_16_03_11_LL_Anaemie_Schwangerschaft_final_1011.pdf">http://www.oeggg.at/fileadmin/user_upload/downloads/Leitlinien/2011_16_03_11_LL_Anaemie_Schwangerschaft_final_1011.pdf</a>]
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Ensayo clínico aleatorizado para evaluar la efectividad de dos vías de administración
                  de hierro, oral e intravenosa, en el tratamiento de la anemia ferropénica posparto
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Merino</span>
                  <span tagx="fnm">SG</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Picado</span>
                  <span tagx="fnm">AL</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Hernández</span>
                  <span tagx="fnm">HM</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Mesa</span>
                  <span tagx="fnm">JM</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Lasa</span>
                  <span tagx="fnm">IL</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Barandiarán</span>
                  <span tagx="fnm">FA</span>
               </li>
            </ul>
            <span tagx="source">Clínica Investigación Ginecol Obstetricia</span>
            <span tagx="pubdate">2012</span>
            <span tagx="volume">39</span>
            <span tagx="fpage">190</span>
            <span tagx="lpage">5</span>
            <div tagx="note">[in Spanish]</div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>A 12-week randomised study comparing intravenous iron sucrose versus oral ferrous
                  sulphate for treatment of postpartum anemia
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Westad</span>
                  <span tagx="fnm">S</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Backe</span>
                  <span tagx="fnm">B</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Salvesen</span>
                  <span tagx="fnm">KÅ</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Nakling</span>
                  <span tagx="fnm">J</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Økland</span>
                  <span tagx="fnm">I</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Borthen</span>
                  <span tagx="fnm">I</span>
               </li>
               <div tagx="etal"></div>
            </ul>
            <span tagx="source">Acta Obstet Gynecol Scand</span>
            <span tagx="pubdate">2008</span>
            <span tagx="volume">87</span>
            <span tagx="fpage">916</span>
            <span tagx="lpage">23</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1080/00016340802317802</span>
                  <span tagx="pubid">18720044</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Intravenous versus oral iron therapy for postpartum anaemia</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Bhandal</span>
                  <span tagx="fnm">N</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Russell</span>
                  <span tagx="fnm">R</span>
               </li>
            </ul>
            <span tagx="source">BJOG Int J Obstetrics Gynaecol</span>
            <span tagx="pubdate">2006</span>
            <span tagx="volume">113</span>
            <span tagx="fpage">1248</span>
            <span tagx="lpage">52</span>
            <div tagx="xrefbib">
               <span tagx="pubid">10.1111/j.1471-0528.2006.01062.x</span>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum
                  anemia: a randomized controlled trial
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">van Wyck</span>
                  <span tagx="fnm">DB</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Martens</span>
                  <span tagx="fnm">MG</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Seid</span>
                  <span tagx="fnm">MH</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Baker</span>
                  <span tagx="fnm">JB</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Mangione</span>
                  <span tagx="fnm">A</span>
               </li>
            </ul>
            <span tagx="source">Obstet Gynecol</span>
            <span tagx="pubdate">2007</span>
            <span tagx="volume">110</span>
            <span tagx="fpage">267</span>
            <span tagx="lpage">78</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1097/01.AOG.0000275286.03283.18</span>
                  <span tagx="pubid">17666600</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Ferric carboxymaltose injection in the treatment of postpartum iron deficiency anemia:
                  a randomized controlled clinical trial
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Seid</span>
                  <span tagx="fnm">MH</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Derman</span>
                  <span tagx="fnm">RJ</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Baker</span>
                  <span tagx="fnm">JB</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Banach</span>
                  <span tagx="fnm">W</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Goldberg</span>
                  <span tagx="fnm">C</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Rogers</span>
                  <span tagx="fnm">R</span>
               </li>
            </ul>
            <span tagx="source">Am J Obstet Gynecol</span>
            <span tagx="pubdate">2008</span>
            <span tagx="volume">199</span>
            <span tagx="fpage">435</span>
            <div tagx="note">e1–7</div>
            <div tagx="xrefbib">
               <span tagx="pubid">18928998</span>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Comparative efficacy and safety of intravenous ferric carboxymaltose in the treatment
                  of postpartum iron deficiency anemia
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Breymann</span>
                  <span tagx="fnm">C</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Gliga</span>
                  <span tagx="fnm">F</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Bejenariu</span>
                  <span tagx="fnm">C</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Strizhova</span>
                  <span tagx="fnm">N</span>
               </li>
            </ul>
            <span tagx="source">Int J Gynecol Obstet</span>
            <span tagx="pubdate">2008</span>
            <span tagx="volume">101</span>
            <span tagx="fpage">67</span>
            <span tagx="lpage">73</span>
            <div tagx="xrefbib">
               <span tagx="pubid">10.1016/j.ijgo.2007.10.009</span>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Intravenous iron therapy versus oral iron in postpartum patients in rural area</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Verma</span>
                  <span tagx="fnm">S</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Inamdar</span>
                  <span tagx="fnm">S</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Malhotra</span>
                  <span tagx="fnm">N</span>
               </li>
            </ul>
            <span tagx="source">J South Asian Federation Obstetrics Gynaecol</span>
            <span tagx="pubdate">2011</span>
            <span tagx="volume">3</span>
            <span tagx="fpage">67</span>
            <span tagx="lpage">70</span>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Intravenous iron sucrose versus oral iron ferrous sulfate for antenatal and postpartum
                  iron deficiency anemia: a randomized trial
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Froessler</span>
                  <span tagx="fnm">B</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Cocchiaro</span>
                  <span tagx="fnm">C</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Saadat-Gilani</span>
                  <span tagx="fnm">K</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Hodyl</span>
                  <span tagx="fnm">N</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Dekker</span>
                  <span tagx="fnm">G</span>
               </li>
            </ul>
            <span tagx="source">J Matern Fetal Neonatal Med</span>
            <span tagx="pubdate">2013</span>
            <span tagx="volume">26</span>
            <span tagx="fpage">654</span>
            <span tagx="lpage">9</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.3109/14767058.2012.746299</span>
                  <span tagx="pubid">23130909</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Intravenous iron in postpartum anemia</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Jain</span>
                  <span tagx="fnm">G</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Palaria</span>
                  <span tagx="fnm">U</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Jha</span>
                  <span tagx="fnm">SK</span>
               </li>
            </ul>
            <span tagx="source">J Obstetrics Gynecol India</span>
            <span tagx="pubdate">2013</span>
            <span tagx="volume">63</span>
            <span tagx="fpage">45</span>
            <span tagx="lpage">8</span>
            <div tagx="xrefbib">
               <span tagx="pubid">10.1007/s13224-012-0240-y</span>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Comparison for Effects of Intravenous versus Oral Iron Therapy for Postpartum Anemia</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Mumtaz</span>
                  <span tagx="fnm">A</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Farooq</span>
                  <span tagx="fnm">F</span>
               </li>
            </ul>
            <span tagx="pubdate">2014</span>
            <div tagx="note">[
               <a href="http://pjmhsonline.com/comparison_for_effects_of_intrav.htm">http://pjmhsonline.com/comparison_for_effects_of_intrav.htm</a>]
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Postpartum anemia I: definition, prevalence, causes, and consequences</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Milman</span>
                  <span tagx="fnm">N</span>
               </li>
            </ul>
            <span tagx="source">Ann Hematol</span>
            <span tagx="pubdate">2011</span>
            <span tagx="volume">90</span>
            <span tagx="fpage">1247</span>
            <span tagx="lpage">53</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1007/s00277-011-1279-z</span>
                  <span tagx="pubid">21710167</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Treatment for women with postpartum iron deficiency anaemia</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Dodd</span>
                  <span tagx="fnm">JM</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Dare</span>
                  <span tagx="fnm">MR</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Middleton</span>
                  <span tagx="fnm">P</span>
               </li>
            </ul>
            <span tagx="source">Cochrane Database Syst Rev</span>
            <span tagx="pubdate">2004</span>
            <span tagx="fpage">CD004222</span>
         </div>
         <div tagx="bibl">
            <ul tagx="aug">
               <li tagx="au">
                  <div tagx="cnm">International Conference on Harmonisation of Technical Requirements for Registration
                     of Pharmaceuticals for Human Use
                  </div>
               </li>
            </ul>
            <span tagx="source">ICH Harmonised Tripartite Guideline - Guideline for Good Clinical Practice E6 (R1)</span>
            <div tagx="publisher">London: European Medicines Agency</div>
            <span tagx="pubdate">2002</span>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>National Board of Health: Healthy Habits – Before, During and After Pregnancy</p>
            </div>
            <span tagx="pubdate">2010</span>
            <div tagx="note">[
               <a href="http://sundhedsstyrelsen.dk/publ/Publ2010/CFF/English/SundeVaner_en.pdf">http://sundhedsstyrelsen.dk/publ/Publ2010/CFF/English/SundeVaner_en.pdf</a>]
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Molecular and cellular mechanisms of iron homeostasis and toxicity in mammalian cells</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Crichton</span>
                  <span tagx="fnm">RR</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Wilmet</span>
                  <span tagx="fnm">S</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Legssyer</span>
                  <span tagx="fnm">R</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Ward</span>
                  <span tagx="fnm">RJ</span>
               </li>
            </ul>
            <span tagx="source">J Inorg Biochem</span>
            <span tagx="pubdate">2002</span>
            <span tagx="volume">91</span>
            <span tagx="fpage">9</span>
            <span tagx="lpage">18</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1016/S0162-0134(02)00461-0</span>
                  <span tagx="pubid">12121757</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument
                  to assess fatigue
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Smets</span>
                  <span tagx="fnm">EM</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Garssen</span>
                  <span tagx="fnm">B</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Bonke</span>
                  <span tagx="fnm">B</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">de Haes</span>
                  <span tagx="fnm">JC</span>
               </li>
            </ul>
            <span tagx="source">J Psychosom Res</span>
            <span tagx="pubdate">1995</span>
            <span tagx="volume">39</span>
            <span tagx="fpage">315</span>
            <span tagx="lpage">25</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1016/0022-3999(94)00125-O</span>
                  <span tagx="pubid">7636775</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Detection of postnatal depression. Development of the 10-item Edinburgh postnatal
                  depression scale
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Cox</span>
                  <span tagx="fnm">JL</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Holden</span>
                  <span tagx="fnm">JM</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Sagovsky</span>
                  <span tagx="fnm">R</span>
               </li>
            </ul>
            <span tagx="source">Br J Psychiatry</span>
            <span tagx="pubdate">1987</span>
            <span tagx="volume">150</span>
            <span tagx="fpage">782</span>
            <span tagx="lpage">6</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1192/bjp.150.6.782</span>
                  <span tagx="pubid">3651732</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Quality of life measurement in patients with transfusion-dependent myelodysplastic
                  syndromes
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Jansen</span>
                  <span tagx="fnm">AJG</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Essink-Bot</span>
                  <span tagx="fnm">M</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Beckers</span>
                  <span tagx="fnm">EAM</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Hop</span>
                  <span tagx="fnm">WCJ</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Schipperus</span>
                  <span tagx="fnm">MR</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">van Rhenen</span>
                  <span tagx="fnm">DJ</span>
               </li>
            </ul>
            <span tagx="source">Br J Haematol</span>
            <span tagx="pubdate">2003</span>
            <span tagx="volume">121</span>
            <span tagx="fpage">270</span>
            <span tagx="lpage">4</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1046/j.1365-2141.2003.04272.x</span>
                  <span tagx="pubid">12694248</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Psychometric evaluation of health-related quality of life measures in women after
                  different types of delivery
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Jansen</span>
                  <span tagx="fnm">AJG</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Essink-Bot</span>
                  <span tagx="fnm">M</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Duvekot</span>
                  <span tagx="fnm">JJ</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">van Rhenen</span>
                  <span tagx="fnm">DJ</span>
               </li>
            </ul>
            <span tagx="source">J Psychosom Res</span>
            <span tagx="pubdate">2007</span>
            <span tagx="volume">63</span>
            <span tagx="fpage">275</span>
            <span tagx="lpage">81</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1016/j.jpsychores.2007.06.003</span>
                  <span tagx="pubid">17719365</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>A systematic review of studies validating the Edinburgh postnatal depression scale
                  in antepartum and postpartum women
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Gibson</span>
                  <span tagx="fnm">J</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">McKenzie-McHarg</span>
                  <span tagx="fnm">K</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Shakespeare</span>
                  <span tagx="fnm">J</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Price</span>
                  <span tagx="fnm">J</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Gray</span>
                  <span tagx="fnm">R</span>
               </li>
            </ul>
            <span tagx="source">Acta Psychiatr Scand</span>
            <span tagx="pubdate">2009</span>
            <span tagx="volume">119</span>
            <span tagx="fpage">350</span>
            <span tagx="lpage">64</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1111/j.1600-0447.2009.01363.x</span>
                  <span tagx="pubid">19298573</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Well being of obstetric patients on minimal blood transfusions (WOMB trial)</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Prick</span>
                  <span tagx="fnm">BW</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Steegers</span>
                  <span tagx="fnm">EA</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Jansen</span>
                  <span tagx="fnm">AG</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Hop</span>
                  <span tagx="fnm">WC</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Essink-Bot</span>
                  <span tagx="fnm">M</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Peters</span>
                  <span tagx="fnm">NC</span>
               </li>
               <div tagx="etal"></div>
            </ul>
            <span tagx="source">BMC Pregnancy Childbirth</span>
            <span tagx="pubdate">2010</span>
            <span tagx="volume">10</span>
            <span tagx="fpage">83</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1186/1471-2393-10-83</span>
                  <span tagx="pubid">3022737</span>
                  <span tagx="pubid">21162725</span>
               </div>
            </div>
         </div>
      </div>
   </div>
</html>